Sarepta Therapeutics | SRPT - Ebitda


Sarepta Therapeutics reported $-3.14M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Daiichi Sankyo JPY 116.06B 14.46B Jun/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD -80.97M 93.7M Sep/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Moderna USD -687M 571M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026